Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colorimetric/Fluorescent/SERS Triple-Mode Synergistic Sensing for Highly Sensitive and Accurate Cardiac Troponin I Detection.

Analytical chemistry·2026
Same author

Ti-Doping Activates Adjacent Zr Sites in Bimetallic MOFs for Cooperative Phospholipid Removals in Human Biomonitoring.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Development of an Integrated CE-Cell-SELEX Strategy for Rational Selection of Human Bone Microvascular Endothelial Cell Aptamers.

Molecules (Basel, Switzerland)·2026
Same author

The effect of multimodal temperature management on the incidence of perioperative hypothermia in patients undergoing general anesthesia: a randomized controlled trial.

BMC anesthesiology·2026
Same author

Hydroxytyrosol attenuates obesity-induced myocardial fibrosis by inhibiting NLRP3/CYLD/NOX4 mediated oxidative stress.

NPJ science of food·2026
Same author

In-Hospital Mortality and Associated Risk Factors in Cardiac Surgery-Related Perioperative Acute Kidney Injury Patients Treated with Continuous Renal Replacement Therapy: A Retrospective Cohort Study.

Journal of cardiothoracic and vascular anesthesia·2026

Related Experiment Video

Updated: May 2, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.2K

SCD2 Alleviates Diabetes-Associated Cognitive Dysfunction by Improving Microglial Lipid Metabolism.

Yang Yang1, Juan He1, Jing Zheng1

  • 1Department of Endocrinology and Metabolism, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

Cell Proliferation
|April 30, 2026
PubMed
Summary

Stearoyl-CoA desaturase 2 (SCD2) deficiency impairs microglial function in diabetes. Restoring SCD2 alleviates neuroinflammation and cognitive deficits in diabetic mice, suggesting therapeutic potential for diabetes-associated cognitive dysfunction.

Keywords:
SCD2diabetes‐associated cognitive dysfunctionlipid droplet accumulationmicroglianeuroinflammationoxidative phosphorylation

More Related Videos

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.1K
Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 26, 2014

42.8K

Related Experiment Videos

Last Updated: May 2, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.2K
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.1K
Barnes Maze Testing Strategies with Small and Large Rodent Models
12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 26, 2014

42.8K

Area of Science:

  • Neuroscience
  • Metabolic Neuroscience
  • Immunology

Background:

  • Diabetes-associated cognitive dysfunction (DACD) mechanisms are unclear, with microglial metabolic dysfunction as a key factor.
  • Stearoyl-CoA desaturase 2 (SCD2) role in microglial lipid metabolism and DACD requires investigation.

Purpose of the Study:

  • To investigate if stearoyl-CoA desaturase 2 (SCD2) alleviates cognitive impairment by modulating microglial lipid metabolism and function.
  • To explore SCD2's therapeutic potential for diabetes-associated cognitive dysfunction.

Main Methods:

  • Bioinformatics analysis of single-cell RNA-seq data (GSE201644) identified SCD2 downregulation in diabetic microglia.
  • In vivo studies involved hippocampal SCD2 overexpression in a type 2 diabetes mouse model using AAV injection.
  • In vitro studies utilized high glucose-treated BV2 microglia-like cells with SCD2 overexpression or oleic acid supplementation.

Main Results:

  • Diabetic microglia showed reduced SCD2, impaired mitochondrial function, and increased lipid droplet accumulation.
  • SCD2 overexpression or oleic acid supplementation rescued mitochondrial function, reduced lipid accumulation, and decreased inflammation.
  • In vivo hippocampal SCD2 overexpression attenuated neuroinflammation, preserved synaptic integrity, and improved cognitive function in diabetic mice.

Conclusions:

  • SCD2 is crucial for maintaining microglial lipid and mitochondrial homeostasis in diabetes.
  • Restoring SCD2 function mitigates neuroinflammation and synaptic deficits, rescuing cognitive impairment in DACD.
  • SCD2 represents a potential therapeutic target for managing diabetes-associated cognitive dysfunction.